Armistice Capital, Llc - Jun 16, 2021 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
10%+ Owner
Signature
Armistice Capital, LLC By: /s/ Steven Boyd, Managing Member
Stock symbol
RSLS
Transactions as of
Jun 16, 2021
Transactions value $
-$14,230,402
Form type
4
Date filed
6/22/2021, 08:58 AM
Previous filing
Jun 22, 2021
Next filing
Jun 29, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock Sale -$2.53M -388K -16.11% $6.52 2.02M Jun 16, 2021 Direct F1, F2
transaction RSLS Common Stock Sale $0 0 0% $0.00* 2.02M Jun 16, 2021 See Footnote 1
transaction RSLS Common Stock Sale -$583K -73.6K -3.64% $7.92 1.95M Jun 16, 2021 Direct F1, F3
transaction RSLS Common Stock Sale $0 0 0% $0.00* 1.95M Jun 16, 2021 See Footnote 1
transaction RSLS Common Stock Sale -$426K -50K -2.57% $8.52 1.9M Jun 16, 2021 Direct F1, F4
transaction RSLS Common Stock Sale $0 0 0% $0.00* 1.9M Jun 16, 2021 See Footnote 1
transaction RSLS Common Stock Sale -$6.35M -1.02M -54.01% $6.20 873K Jun 17, 2021 Direct F1, F5
transaction RSLS Common Stock Sale $0 0 0% $0.00* 873K Jun 17, 2021 See Footnote 1
transaction RSLS Common Stock Sale -$580K -81.4K -9.32% $7.13 791K Jun 17, 2021 Direct F1, F6
transaction RSLS Common Stock Sale $0 0 0% $0.00* 791K Jun 17, 2021 See Footnote 1
transaction RSLS Common Stock Sale -$3.76M -686K -86.62% $5.48 106K Jun 18, 2021 Direct F1, F7
transaction RSLS Common Stock Sale $0 0 0% $0.00* 106K Jun 18, 2021 See Footnote 1 F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities (the "Shares") of ReShape Lifesciences Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and together with Armistice Capital, the "Reporting Persons"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2 This constitutes the weighted average purchase price. The prices range from $5.96 to $6.86. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price.
F3 This constitutes the weighted average purchase price. The prices range from $7.30 to $8.06. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price.
F4 This constitutes the weighted average purchase price. The prices range from $8.46 to $8.54. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price.
F5 This constitutes the weighted average purchase price. The prices range from $5.86 to $6.84. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price.
F6 This constitutes the weighted average purchase price. The prices range from $6.91 to $7.51. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price.
F7 This constitutes the weighted average purchase price. The prices range from $5.30 to $5.86. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price.
F8 Additionally, the Reporting Persons no longer have beneficial ownership of 13,333 Shares as a result of the settlement of a transaction made prior to the reporting period. Accordingly, the Reporting Persons have beneficial ownership of 92,540 Shares.